Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung02: rilvegostomig plus platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy in first-line PD-L1-positive squamous NSCLC
2024-514281-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Rilvegostomig + platinum-based chemotherapy with Pembrolizumab + platinum-based chemotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
rilvegostomigpembrolizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2024-514281-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514281-39-00.